Schedule 13G ownership disclosure
MOONLAKE IMMUNOTHERAPEUTICS
COMMON STOCK · CUSIP: 61559X104
Event date: 2025-03-31
- Filing-level shares
- 2,974,271
- Percent of class
- 4.7%
- T. Rowe Price Associates, Inc.
Shares: 2,974,271 · Class: 4.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000080255-25-000373
- Form type
- SCHEDULE 13G/A
- Filer
- MoonLake Immunotherapeutics
- CIK
- CIK 1821586
- Filed
- May 14, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership